Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

FOX 32's Elizabeth Matthews shares her painful and vision-threatening battle with shingles on her face and eye to raise awareness that the illness can strike younger, healthy adults.

Shingles, also called herpes zoster, is a condition caused by the same virus as chickenpox. About 350,000 Americans get chickenpox each year, which causes an itchy rash that lasts about a week.